Hims & Hers to Offer Eli Lilly's Weight-Loss Drugs

What happened

Hims & Hers Health and Eli Lilly agreed that patients prescribed Lilly’s obesity drugs through Hims & Hers’ platform can access the same self-pay prices available elsewhere. The medicines are Zepbound and Foundayo, with starting monthly prices of $299 and $149, respectively.

Confirmed

Global impact / market context

The deal gives Lilly another way to reach people seeking obesity treatment and may help it compete with Novo Nordisk. By offering Lilly’s drugs alongside Novo’s Wegovy, Hims & Hers could attract more patients to its platform, potentially increasing prescription activity and revenue from its telehealth service.

Analyst inference

The article describes fierce competition in the GLP-1 drug market, a class of medicines that includes treatments for obesity. Lilly is using Hims & Hers’ large user base and telehealth access to reach patients, while matching the self-pay prices available elsewhere.

Confirmed

What to watch

1. Whether patients use the new telehealth access to obtain Zepbound or Foundayo, and whether Lilly reports that the agreement expands its reach among adults with obesity. Analyst inference
2. Whether Hims & Hers provides further details on prescriptions or patient uptake; the article confirms access for patients with a platform-provider prescription but gives no volume targets. Analyst inference
3. Whether Lilly or Hims & Hers disclose changes to the listed self-pay starting prices of $149 monthly for Foundayo and $299 monthly for Zepbound. Analyst inference

Evidence

• Original source link unavailable